FDA Cuts Monitoring Time for Amgen's Imdelltra Infusions

The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen's Imdelltra, reducing the monitoring time for patients with extensive-stage small cell lung cancer after their first two infusions.

The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight hours in an appropriate healthcare setting following the initial two doses of Imdelltra, replacing the previous requirement for 22 to 24 hours of observation.

Patients will also receive a follow-up assessment, including vital signs, the day after each of these first two doses. For subsequent doses, the monitoring requirements remain unchanged: six to eight hours for the third dose and throughout Cycle 2, three to four hours for Cycles 3 to 4, and two hours for Cycle 5 and beyond.

The updated label also advises patients to remain within one hour of suitable medical facilities for 48 hours from the start of the first and eighth day infusions, accompanied by a caregiver. Amgen highlighted that this regulatory decision could cut the need for patients to spend extended periods in healthcare settings during the early stages of treatment.